Csf Biomarker Levels In Early And Classic Onset Of Alzheimer'S Disease

To compare CSF levels of beta-amyloid 1-42(Abeta(1-42)), total tau (Tau) and tau phosphorylated at threonine 181 (pTau-181) between AD patients with different age of onset and controls. Eighty eight AD patients (mean age and SD, 74.29 ± 5.41) with classic onset of the disease (365 years), 35AD patients (mean age and SD, 54.66 ± 5.38) with early onset 50 control subjects (mean age and SD, 70.15 plus or minus 11.10) underwent lumbar puncture. The Innotest ELISA sandwich test (Innogenetics-Belgium) was used for measuring the levels of Tau, pTau-181 and Abeta (1-42). All three biomarkers showed main effects of the diagnosis. When series of ANCOVAs with age as covariate were performed, the significant difference still exists. There were no differences between AD patients with early and classic onset of the disease in the levels of a) Abeta (1-42) 449 ± 209 versus 460 ± 206 pg/ml; b) Tau 697 ± 603 versus 549 ± 298 pg/ml; c) pTau-181 130 ± 88 versus 131 ± 73 pg/ml). The CSF biomarkers may be supportive in the diagnosis of AD in routine clinical practice considering the approaching new target therapeutics.